926037-48-1

Basic information

• Product Name: Supect
• Synonyms: IY5511;Radotinib;Supect;Radotinib(IY-5511);4-Methyl-N-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-(4-(pyrazin-2-yl)pyrimidin-2-ylamino)benzamide
• CAS NO: 926037-48-1
• Molecular Formula: C27H21F3N8O
• Molecular Weight: 530.5038496
• Product Categories: Inhibitors
• Mol File: 926037-48-1.mol

Chemical Properties

• Appearance: /
• Density: 1.40±0.1 g/cm3(Predicted)
• Solubility: ≥26.55 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O
• PKA: 12.94±0.70(Predicted)
• CAS DataBase Reference: Supect(CAS DataBase Reference)
• NIST Chemistry Reference: Supect(926037-48-1)
• EPA Substance Registry System: Supect(926037-48-1)

Safety Data

• Hazardous Substances Data: 926037-48-1(Hazardous Substances Data)

Usage

Uses

Used in Oncology:
Supect is used as a second-line treatment for chronic myeloid leukemia (CML) due to its potent activity against tumor cell lines and its ability to inhibit the Bcr-Abl tyrosine kinase.
Used in Anticancer Applications:
Supect is used as a potential target agent for the treatment of acute myeloid leukemia and small cell lung cancer, as it can induce cytotoxicity in c-KIT-positive malignancies.
Used in COVID-19 Research:
Supect is a COVID-19-related research product, indicating its potential use in studying and treating the virus.
Used in Pharmaceutical Industry:
Supect is used as a tyrosine kinase inhibitor in the development of novel drug delivery systems to enhance its applications and efficacy against cancer cells.

Originator

Il-Yang (Korea)

Indications

Radotinib (Supect(R), Il-Yang Pharmaceutical) is a Bcr–Abl inhibitor that was approved in South Korea in 2012 for the treatment of imatinib-resistant CML. Radotinib, which has a terminal 4-(pyridine-2-yl) pyrimidine moiety, was developed based on the previously approved Bcr–Abl inhibitors nilotinib. Radotinib has equivalent efficacy with that of other second-generation Bcr–Abl inhibitors and is well tolerated in chronic-phase CML patients. The lower cost of radotinib compared with other FDA-approved Bcr–Abl inhibitors makes it an attractive alternative for the treatment of CML in developing nations.

in vitro

radotinib couples to bcr-abl and reduce the phosphorylation of bcr-abl target protein crkl. the pre-clinical studies shows superiority of radotinib to imatinib in both wild-type and mutant bcr-abl1 positive cml cell lines. [1]

references

1. kim sh, menon h, jootar s et al. efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to bcr-abl1 tyrosine kinase inhibitors. haematologica. 2014 jul;99(7):1191-6.

Upstream product

• 641571-11-1 3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)aniline 
• 6946-14-1 3-acetylamino-4-methylbenzoic acid 
• 111781-53-4 3-dimethylamino-1-(3-pyrazinyl)-2-propene-1-one 
• 1207665-72-2 4-methyl-3-(4-pyrazine-2-yl-pyrimidine-2-yl-amino)-benzoic acid phenyl ester 
• 1207665-71-1 4-methyl-3-(4-pyrazine-2-yl-pyrimidine-2-yl-amino)-benzoic acid methyl ester 
• 926038-04-2 4-methyl-3-(4-pyrazine-2-yl-pyrimidine-2-yl-amino)-benzoic acid ethyl ester 

Relevant articles and documents

High-yield synthesis method of radotinib

The invention discloses a high-yield synthesis method of radotinib and relates to the technical field of drug organic synthesis. The method comprises the following steps that 3-acetamido-4-methylbenzoic acid as a starting raw material undergoes an amide condensation reaction with 3-(4-methyl-1H-imidazol-1-yl)-5-trifluoromethylaniline to obtain an intermediate I, the intermediate I and cyanamide undergo an addition reaction to obtain an intermediate II, and the intermediate II and dimethylamino-1-(3-pyrazinyl)-2-propenyl-1-one undergo a ring-closure reaction to obtain radotinib. According to the method, the reaction operation is simplified, the cost investment is reduced, the generation amount of three wastes is reduced, the conversion rate of initial raw materials and intermediates is increased, and the total yield of the prepared radotinib can reach 79% or above.

PROCESS FOR THE PREPARATION OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES

Disclosed is a novel method of preparing an N-phenyl-2-pyrimidine-amine derivative. As compared to a conventional method, the disclosed preparation method is efficientin that the method requires low production cost due to production process reduction, a simplified purification method, and high yield/purity by a selective reaction, and also is environmentally friendly and consistent.

N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF

The present invention relates to a novel N-phenyl-2-pyrimidine-amine derivative represented by the above formula (1) and its salt showing a superior effect on cancer in warm-blooded animals, such as lung cancer, gastric cancer, colon cancer, pancreatic cancer, hepatoma, prostatic cancer, breast cancer, chronic or acute leukemia, hematologic malignancy, encephalophyma, bladder cancer, rectal cancer, cervical cancer, lymphoma, etc. The present invention also relates to a process for preparing the compound, and to a pharmaceutical composition for the treatment of the above various diseases, which comprises an effective amount of the compound as an active ingredient together with pharmaceutically acceptable inert carriers.